BME - BlackRock Health Sciences Trust

What this means for you

No investor has reported owning 5% or more of this fund. That is the normal state for most closed-end funds.

Nothing is required of you. If that changes, the notice appears here within a day of being filed with the regulator.

Email me if this changes

What happened, and when

1. Feb 25, 2025

   The buy-back ended; the fund paid $42.1792 a share.

   Original document →

2. Feb 24, 2025

   The buy-back ended; an early count says holders offered 9% of all shares.

   Original document →

3. Jan 22, 2025

   The fund offered to buy back 2.5% of its shares at 98% of value, until Feb 21, 2025.

   Original document →

4. Dec 23, 2024

   The fund said it may sell new shares.

   Original document →

5. Nov 20, 2024

   The buy-back ended; the fund paid $41.2678 a share.

   Original document →

About this fund

• Run by BlackRock Advisors, LLC. Part of the BlackRock-advised Funds fund family. As of Dec 31, 2025, from the fund's yearly report. Original document →
• Size: about $571 million of holdings, as of June 30, 2026. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
• Borrowing: the fund does not borrow. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
• Costs: 1% a year in management fees; 1.1% a year in total, including interest on borrowed money. Fiscal year ended Dec 31, 2025. As of Dec 31, 2025, from the fund's yearly report. Original document →
• Payouts: last fiscal year (ended Dec 31, 2025) the fund paid $3.15 a share. $0.11 of that was income; $2.30 came from gains; $0.74 was your own money back, not income. As of Dec 31, 2025, from the fund's annual report. Original document →
• Value of holdings per share at the last fiscal year end (Dec 31, 2025): $43.97. The shares traded at $41.13, about 6.5% below that. As of Dec 31, 2025, from the fund's yearly report. Original document →
  Over the last two years the gap ranged from 9.6% below to 0.1% above. As of June 30, 2025, from the fund's annual report. Original document →
• How the holdings did: up 9.4% over the last three months we have (April-June 2026), before the share price is taken into account. Over the last 12 months: +21.7%. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
• How the holdings did over the fiscal year (ended Dec 31, 2025): the value of the holdings returned +15.8%. How the share price did: the shares returned +17.7% over the same year, counting payouts and the change in the market price. As of Dec 31, 2025, from the fund's annual report. Original document →
• First reported to the regulator in 2005.

What the fund holds

Mostly shares (96%), the rest cash and short-term holdings. About 94% issued in the U.S.

1. Eli Lilly & - 12.5%
2. Johnson & Johnson - 7.8%
3. UnitedHealth Group - 6.1%
4. Merck & - 5.2%
5. AbbVie - 5.1%
6. Gilead Sciences - 3.7%
7. Cash and short-term - 3.7%
8. Amgen - 3.4%
9. Thermo Fisher Scientific - 3%
10. Vertex Pharmaceuticals - 2.8%

As of June 30, 2026, from the fund's quarterly holdings report. Original document →